Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Wunderlich

Showing results (101-110 of 112) with videos related to

Pageof 12
Sort By:
Blood|November 14, 2025
Glutaredoxin 2 is essential for AML survival through mitochondrial permeability transition pore regulationTianyi Ling, Cristiana O'Brien, Jonathan St-Germain, et al.
Nature Communications|December 14, 2017
Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemiaXi Jiang, Chao Hu, Kyle Ferchen, et al.
Nature Communications|February 11, 2018
Author Correction: Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemiaXi Jiang, Chao Hu, Kyle Ferchen, et al.
JCI Insight|April 22, 2024
Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemiaOla A Elgamal, Sydney Fobare, Sandip Vibhute, et al.
Blood|June 5, 2026
Targeting the METTL1/m⁷G axis as a therapeutic strategy in myeloid leukemiaLili Ren, Honghai Zhang, Olga Bobileva, et al.
Cancer Cell|June 13, 2020
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune EvasionRui Su, Lei Dong, Yangchan Li, et al.
Cell Reports|December 30, 2015
MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199Juliana M Benito, Laura Godfrey, Kensuke Kojima, et al.
Science Translational Medicine|March 9, 2022
Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemiaLaura Barreyro, Avery M Sampson, Chiharu Ishikawa, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2025
Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric LeukemiaKe Wang, Shayan Saniei, Nikita Poddar, et al.
Cancer Discovery|December 6, 2025
Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric LeukemiaKe Wang, Shayan Saniei, Nikita Poddar, et al.
Pageof 12

Showing results (101-110 of 112) with videos related to

Sort By:
Pageof 12
Blood|November 14, 2025
Glutaredoxin 2 is essential for AML survival through mitochondrial permeability transition pore regulationTianyi Ling, Cristiana O'Brien, Jonathan St-Germain, et al.
Nature Communications|December 14, 2017
Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemiaXi Jiang, Chao Hu, Kyle Ferchen, et al.
Nature Communications|February 11, 2018
Author Correction: Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemiaXi Jiang, Chao Hu, Kyle Ferchen, et al.
JCI Insight|April 22, 2024
Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemiaOla A Elgamal, Sydney Fobare, Sandip Vibhute, et al.
Blood|June 5, 2026
Targeting the METTL1/m⁷G axis as a therapeutic strategy in myeloid leukemiaLili Ren, Honghai Zhang, Olga Bobileva, et al.
Cancer Cell|June 13, 2020
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune EvasionRui Su, Lei Dong, Yangchan Li, et al.
Cell Reports|December 30, 2015
MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199Juliana M Benito, Laura Godfrey, Kensuke Kojima, et al.
Science Translational Medicine|March 9, 2022
Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemiaLaura Barreyro, Avery M Sampson, Chiharu Ishikawa, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2025
Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric LeukemiaKe Wang, Shayan Saniei, Nikita Poddar, et al.
Cancer Discovery|December 6, 2025
Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric LeukemiaKe Wang, Shayan Saniei, Nikita Poddar, et al.
Pageof 12